Drug Trial Radar · NCT05979818
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
118
Planned (sponsor's estimate)
Start
Nov 13, 2024
Primary completion
Oct 31, 2028
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Innovent Biologics (Suzhou) Co. Ltd.
- First posted
- Aug 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective multi-center Phase Ib/II clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta-adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.
Conditions
- Non Small Cell Lung Cancer
- Propranolol
- Immune Checkpoint Inhibitors
- Immunotherapy
- β-adrenergic Antagonists
- Emotional Distress
- PD-1 Inhibitors
Interventions
Propranolol hydrochlorideDrug
Dose-escalation: 10 mg PO BID, 10 mg PO TID, and 20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
SintilimabDrug
intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
ChemotherapyDrug
Platinum-based chemotherapy: For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4/6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Propranolol hydrochloride matching placeboDrug
20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Propranolol Hydrochloride R2PDDrug
20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs) (BRIO-I)Time frame: 2 years
- Recommended phase II dose (RP2D) (BRIO-I)Time frame: 2 years
- Objective Response Rate (ORR) (BRIO-I)Time frame: 2 years
- Progression-free survival (PFS) (BRIO-II)Time frame: 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The Second Xiangya Hospital of Central south University
Changsha, Hunan, China · Recruiting
Xiangya hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.